PMID: 20647645Jul 22, 2010Paper

Relation between the antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from respiratory specimens and antimicrobial use density (AUD) from 2005 through 2008

Internal Medicine
Yasutsugu FukushimaTakeshi Fukuda

Abstract

To examine the relation between annual trends in the antimicrobial susceptibility of Pseudomonas aeruginosa and drug usage, we compared annual changes in the susceptibility rates of P. aeruginosa clinical isolates during a 4-year period and annual trends in the overall usage of antimicrobials during the same period. We studied annual trends in MIC(90)/MIC(50), antimicrobial use density (AUD), and antimicrobial susceptibility rates based on clinical breakpoints for 150 strains of P. aeruginosa isolated from respiratory specimens at Dokkyo Medical University Hospital from 2005 through 2008. The MIC(90)/MIC(50) of antimicrobials effective against P. aeruginosa in years 2005, 2006, 2007, and 2008 were as follows: imipenem, 32/2, 32/1, 8/2, and 16/1 microg/mL; meropenem, 8/1, 8/1, 4/0.5, and 4/0.5 microg/mL; and biapenem, 16/1, 32/0.5, 4/0.5, and 8/0.5 microg/mL, indicating that susceptibility to carbapenems increased slightly. The MIC(90)/MIC(50) was 4/0.25, 2/0.125, 1/0.125, and 2/0.25 microg/mL for ciprofloxacin, 8/4, 8/4, 4/4, and 8/4 microg/mL for amikacin, 64/16, 64/16, 64/16, and 64/16 microg/mL for sulbactam/cefoperazone, 8/2, 16/2, 32/2, and 8/2 microg/mL for ceftazidime, indicating little change. The AUDs of fourth-generat...Continue Reading

References

Aug 1, 1986·The Journal of Infectious Diseases·J P QuinnS A Lerner
Aug 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A C WhiteS B Greenberg
Jan 30, 1999·Antimicrobial Agents and Chemotherapy·T KöhlerJ C Pechere
Feb 13, 2001·Antimicrobial Agents and Chemotherapy·H PaiN Gotoh
Feb 27, 2001·The Journal of Antimicrobial Chemotherapy·D M Livermore
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Alan Patrick GibbNeil Woodford
Jan 15, 2003·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kiyomi OkamotoTakeshi Nishino
Feb 18, 2003·JAMA : the Journal of the American Medical Association·Melinda M NeuhauserJohn P Quinn
Jan 14, 2004·Drugs·Xian-Zhi Li, Hiroshi Nikaido
Apr 28, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akiyoshi TsujiSachiko Goto
Oct 8, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T R Walsh
Jan 5, 2006·Applied Microbiology and Biotechnology·S Jana, J K Deb
Dec 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James H Jorgensen, Janet F Hindler
Mar 1, 2008·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Hiroaki Miyazaki

❮ Previous
Next ❯

Citations

May 12, 2011·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Rodrigo Pires dos SantosLuciano Zubaran Goldani
Oct 7, 2011·Expert Review of Anti-infective Therapy·Matteo BassettiDaniele Roberto Giacobbe
Jun 24, 2017·The Journal of Antimicrobial Chemotherapy·A Peter R Wilson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.